MX2016006271A - Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas. - Google Patents

Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.

Info

Publication number
MX2016006271A
MX2016006271A MX2016006271A MX2016006271A MX2016006271A MX 2016006271 A MX2016006271 A MX 2016006271A MX 2016006271 A MX2016006271 A MX 2016006271A MX 2016006271 A MX2016006271 A MX 2016006271A MX 2016006271 A MX2016006271 A MX 2016006271A
Authority
MX
Mexico
Prior art keywords
solid forms
hydroxypyridine
chlorophenyl
carbonyl
amino
Prior art date
Application number
MX2016006271A
Other languages
English (en)
Inventor
Densmore Copp James
W Newman Ann
Luong Anne
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of MX2016006271A publication Critical patent/MX2016006271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan en la presente formas sólidas que comprenden ácido { [5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acétic o, composiciones que comprenden las formas sólidas, métodos para elaborar las formas sólidas y métodos de su uso para el tratamiento de diversa enfermedades y/o trastornos.
MX2016006271A 2013-11-15 2014-11-14 Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas. MX2016006271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904803P 2013-11-15 2013-11-15
PCT/US2014/065631 WO2015073779A1 (en) 2013-11-15 2014-11-14 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
MX2016006271A true MX2016006271A (es) 2017-05-04

Family

ID=53058045

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016006271A MX2016006271A (es) 2013-11-15 2014-11-14 Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
MX2021001169A MX2021001169A (es) 2013-11-15 2014-11-14 Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
MX2021007268A MX2021007268A (es) 2013-11-15 2016-05-13 Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021001169A MX2021001169A (es) 2013-11-15 2014-11-14 Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
MX2021007268A MX2021007268A (es) 2013-11-15 2016-05-13 Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.

Country Status (24)

Country Link
US (7) US9701636B2 (es)
EP (2) EP3578546A1 (es)
JP (4) JP2016537365A (es)
KR (2) KR102495018B1 (es)
CN (2) CN114890943A (es)
AR (2) AR099354A1 (es)
AU (4) AU2014348523B2 (es)
BR (1) BR112016011065B1 (es)
CA (1) CA2930128A1 (es)
CL (1) CL2016001150A1 (es)
CR (2) CR20160222U (es)
DO (1) DOP2016000109A (es)
IL (2) IL245634A0 (es)
MA (1) MA39033A1 (es)
MX (3) MX2016006271A (es)
MY (1) MY180626A (es)
PE (1) PE20160945A1 (es)
PH (1) PH12016500866A1 (es)
RU (2) RU2021125455A (es)
SA (1) SA516371129B1 (es)
SG (2) SG10201803862UA (es)
TW (3) TW201946625A (es)
WO (1) WO2015073779A1 (es)
ZA (2) ZA201603189B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3026044T3 (pl) 2006-06-26 2019-04-30 Akebia Therapeutics Inc Inhibitory prolilo-hydroksylazy i sposoby ich użycia
NO2686520T3 (es) 2011-06-06 2018-03-17
DK3007695T3 (da) 2013-06-13 2024-03-18 Akebia Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af anæmi
JP2016537365A (ja) 2013-11-15 2016-12-01 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
US20160339005A1 (en) * 2014-01-23 2016-11-24 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
HRP20211862T1 (hr) 2015-04-01 2022-03-04 Akebia Therapeutics, Inc. Pripravci za i postupci liječenja anemije
CN105837502A (zh) * 2016-04-05 2016-08-10 湖南欧亚生物有限公司 一种Vadadustat的合成方法
EP3763703A3 (en) 2016-12-13 2021-03-03 Crystal Pharmaceutical (Suzhou) Co., Ltd. Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and processes for preparation thereof
WO2019028150A1 (en) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
AR114886A1 (es) 2018-05-09 2020-10-28 Akebia Therapeutics Inc Proceso para preparar ácido 2-[[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino]acético
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
WO2020108941A1 (en) 2018-11-28 2020-06-04 Sandoz Ag Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
IT202000014116A1 (it) * 2020-06-12 2021-12-12 Olon Spa Nuovo composto cristallino di vadadustat
EP4181873A1 (en) * 2020-06-19 2023-05-24 Akebia Therapeutics Inc. Modulation of drug-drug interactions of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
WO2022048613A1 (zh) * 2020-09-04 2022-03-10 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
AU2022206302A1 (en) 2021-01-08 2023-08-17 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
AU2022229275A1 (en) * 2021-03-01 2023-10-12 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
BR8807740A (pt) 1988-07-25 1990-10-16 V Kurgansky Nauchny Ts Vosstan Aparelho de tracao para reconstrucao plastica da mao
TW219933B (es) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE149485T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
EP0900202A1 (de) 1996-04-30 1999-03-10 Hoechst Aktiengesellschaft 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
JP4495339B2 (ja) 1998-03-23 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド ピペリジニルおよびｎ−アミジノピペリジニル誘導体
ATE334993T1 (de) 1998-08-27 2006-08-15 Teva Pharma Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten
EP1133459B1 (en) 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form v
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
MXPA02001369A (es) 1999-08-11 2005-08-26 Teva Pharma Torasemidas polimorfas.
PL355805A1 (en) 1999-11-17 2004-05-17 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CN1434702A (zh) 1999-12-14 2003-08-06 拜奥盖尔药厂有限公司 新的帕伐他丁钠形式
RU2002116232A (ru) 1999-12-16 2004-01-10 Тева Фамэситикл Индастрис Лтд. (Il) Способ получения полиморфных модификаций кларитромицина и новой полиморфной модификации IV
JP2003517011A (ja) 1999-12-16 2003-05-20 テバ ファーマシューティカル インダストリーズ リミティド レフルノミドの新規な製法及び新しい結晶形態
HUP0204010A3 (en) 1999-12-21 2006-02-28 Teva Pharma Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and their use
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
DK1280535T3 (da) 2000-01-11 2005-04-04 Teva Pharma Processer til fremstilling af clarithromycin polymorfer
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
SK2242003A3 (en) 2000-07-27 2003-10-07 Teva Pharma Crystalline and pure modafinil, and process of preparing the same
WO2002045658A2 (en) 2000-10-19 2002-06-13 Teva Pharmaceutical Industries Ltd. Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20020183553A1 (en) 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
AU2002230935A1 (en) 2000-10-30 2002-05-15 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
US6605636B2 (en) 2000-11-03 2003-08-12 Teva Pharmaceutical Industries Ltd. Atorvastatin hemi-calcium form VII
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2437402A1 (en) 2001-02-12 2002-08-22 Teva Pharmaceutical Industries, Ltd. New crystal forms of oxcarbazepine and processes for their preparation
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
EP1392303A4 (en) 2001-04-09 2005-01-26 Teva Pharma FEXOFENADINE HYDROCHLORIDE POLYMORPHS
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
CZ200471A3 (cs) 2001-08-01 2004-11-10 Biogal Gyogyszergyar Rt Způsob purifikace N-[3-(3-kyanopyrazol[1,5-a]pyrimidin-7-yl)fenyl]-N-ethylacetamidu (zaleplon) a krystalické formy zaleplonu připravitelné tímto způsobem
EP1436295A4 (en) 2001-09-07 2007-07-11 Teva Pharma CRISTALLINE FORMS OF VALACYCLOVIR HYDROCHLORIDE
DE60215213T3 (de) 2001-10-03 2010-07-01 Teva Pharmaceutical Industries Ltd. Herstellung von levofloxacin-hemihydrat
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003039482A2 (en) 2001-11-08 2003-05-15 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine base
HUP0501067A2 (en) 2001-11-14 2006-02-28 Teva Pharma Amorphous and crystalline forms of losartan potassium and process for their preparation
US6734314B2 (en) 2001-12-04 2004-05-11 Biogal Gyogyszergyar Rt. Preparation of orlistat and orlistat crystalline forms
DK2289531T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc Medications for the treatment or prevention of anemia
CA2470479A1 (en) 2001-12-18 2003-06-26 Teva Pharmaceutical Industries Ltd. Polymorphs of clopidogrel hydrogensulfate
CA2460970C (en) 2001-12-28 2005-10-18 Biogal Gyogyszergyar Rt Processes for preparing crystalline and amorphous mupirocin calcium
JP2005515226A (ja) 2002-01-15 2005-05-26 テバ ファーマシューティカル インダストリーズ リミティド カルベジロールの結晶質固体及びそれらを調製するための方法
ES2241507T1 (es) 2002-02-15 2005-11-01 Teva Pharmaceutical Industries Ltd. Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica.
US20030216376A1 (en) 2002-03-20 2003-11-20 Revital Lifshitz-Liron Crystalline forms of quetiapine hemifumarate
MXPA04009384A (es) 2002-03-27 2005-01-25 Teva Pharma Polimorfos de lansoprazol y proceso para la preparacion de los mismos.
US20030195170A1 (en) 2002-04-11 2003-10-16 Judith Aronhime Novel polymorphs and pseudopolymorphs of risedronate sodium
EP1499581A1 (en) 2002-04-29 2005-01-26 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
EP1465887A1 (en) 2002-04-30 2004-10-13 Teva Gyogyszergyar Reszvenytarsasag Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
CN1665504A (zh) 2002-05-10 2005-09-07 特瓦制药工业有限公司 新晶型的加替沙星
JP2005532356A (ja) 2002-06-10 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド 塩酸フェキソフェナジンの多型体ｘｖｉ
JP2005532364A (ja) 2002-06-14 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの新規結晶質形態
WO2004009532A1 (en) 2002-07-18 2004-01-29 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US20040022764A1 (en) * 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
AU2003258109A1 (en) 2002-08-06 2004-02-23 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
AU2003268213A1 (en) 2002-08-26 2004-03-11 Teva Pharmaceutical Industries Ltd. Crystalline solid famciclovir forms i, ii, iii and preparation thereof
US20050043329A1 (en) 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
EP1572643A2 (en) 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
EP1485097A1 (en) 2002-12-12 2004-12-15 Teva Pharmaceutical Industries Limited Crystalline forms of gatifloxacin and processes for preparation
EP1575962A1 (en) 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
PL1507531T3 (pl) 2003-03-12 2007-06-29 Teva Pharma Trwałe kompozycje farmaceutyczne desloratadyny
EP1601667A2 (en) 2003-03-12 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline and amorphous solids of pantoprazole and processes for their preparation
WO2004083192A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd. Polymorphis of valsartan
US7452991B2 (en) 2003-05-15 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Aztreonam β polymorph with very low residual solvent content
TW200510414A (en) 2003-06-02 2005-03-16 Teva Pharma Novel crystalline forms of valacyclovir hydrochloride
CA2528100A1 (en) 2003-06-03 2005-04-21 Teva Pharmaceutical Industries Ltd Polymorphic forms of ziprasidone hcl and processes for their preparation
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
PT1638937E (pt) 2003-06-18 2009-01-27 Teva Pharma Forma xiv cristalina de fluvastatina sódica, processos para a sua preparação, composições que a contêm e métodos de utilização
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1567533B1 (en) 2003-07-03 2009-03-11 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
EP1594493A2 (en) 2003-12-16 2005-11-16 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
WO2005058835A2 (en) 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
EP1592688A2 (en) 2003-12-18 2005-11-09 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
EP1709002A2 (en) 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
US20050187243A1 (en) 2004-01-30 2005-08-25 Valerie Niddam-Hildesheim Montelukast free acid polymorphs
WO2005077941A2 (en) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
US20050256163A1 (en) 2004-04-26 2005-11-17 Ilan Kor Crystalline forms of fexofenadine hydrochloride and processes for their preparation
MXPA06012793A (es) 2004-05-07 2007-07-18 Teva Pharma Formas polimorficas de nateglinida.
EP1747223A1 (en) 2004-05-18 2007-01-31 Teva Pharmaceutical Industries Ltd. Drying process for preparing crystalline solid famciclovir
US20050272821A1 (en) 2004-05-20 2005-12-08 Valeriano Merli Levalbuterol hydrochloride Polymorph A
WO2006002348A2 (en) 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
EP1658275A1 (en) 2004-06-29 2006-05-24 Teva Pharmaceutical Industries Ltd Crystalline form iv of linezolid
CA2576307A1 (en) 2004-07-01 2006-03-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of 1,24(s)-dihydroxy vitamin d2
US7439373B2 (en) 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
CA2575243A1 (en) 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
US7473804B2 (en) 2004-07-22 2009-01-06 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
KR20090120011A (ko) 2004-08-23 2009-11-23 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
US20060154957A1 (en) 2004-09-21 2006-07-13 Nina Finkelstein Crystalline clopidogrel hydrobromide and processes for preparation thereof
WO2006037042A1 (en) 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Fexofenadine crystal form and processes for its preparation thereof
CA2582092A1 (en) 2004-11-02 2006-05-11 Teva Pharmaceutical Industries Ltd. Tadalafil crystal forms and processes for preparing them
WO2006050509A2 (en) 2004-11-03 2006-05-11 Teva Pharmaceutical Industries Ltd. Amorphous and polymorphic forms of telmisartan sodium
EP1812428A2 (en) 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
JP2007523069A (ja) 2004-12-01 2007-08-16 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 非吸湿性及び粉末性非晶質ピメクロリマス
WO2006060808A1 (en) 2004-12-03 2006-06-08 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
DE602006009619D1 (de) 2005-01-11 2009-11-19 Teva Pharm Fine Chemicals Srl Verfahren zur herstellung von 1-amino-3,5-dimethyladamantan-hydrochlorid
EP1776049A2 (en) 2005-01-27 2007-04-25 Teva Pharmaceutical Industries Ltd. Duloxetine hcl polymorphs
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
WO2006091656A1 (en) 2005-02-24 2006-08-31 Teva Pharmaceutical Industries, Ltd Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
US7291614B2 (en) 2005-02-24 2007-11-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
MX2007010931A (es) 2005-03-08 2007-10-16 Teva Pharma Formas cristalinas de (s)-(+)-n,n-dimetil-3-(1-naftaleniloxi)-3-(2 -tienil)propanamina oxalato y la preparacion ellas.
WO2006098834A2 (en) 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
WO2006108151A1 (en) 2005-04-06 2006-10-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
CN101180261A (zh) 2005-05-23 2008-05-14 特瓦制药工业有限公司 用于制备盐酸西那卡塞晶型ⅰ的方法
AR053295A1 (es) 2005-05-23 2007-04-25 Cadbury Adams Usa Llc Composiciones que potencian el sabor y golosinas comestibles y productos de goma de mascar que los contienen
CN101394843A (zh) 2005-06-06 2009-03-25 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
WO2006135757A1 (en) 2005-06-09 2006-12-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
US20070100165A1 (en) 2005-06-09 2007-05-03 Ronen Borochovitz Process for preparation of sertraline hydrochloride form I
WO2006138511A2 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
MX2007002113A (es) 2005-06-22 2007-04-27 Teva Pharma Formas polimorfas de maleato de tegaserod.
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007038676A2 (en) 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
SI1937642T1 (sl) 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
EP1943256A2 (en) 2005-10-31 2008-07-16 Teva Pharmaceutical Industries Ltd. Crystalline forms of cefdinir potassium salt
JP2008526782A (ja) 2005-10-31 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド セフジニルセシウム塩結晶
WO2007059307A2 (en) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
CA2625299A1 (en) 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Crystal forms of cinacalcet hci and processes for their preparation
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
BRPI0610344A2 (pt) 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
EP1968588A2 (en) 2006-01-05 2008-09-17 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Crystalline forms of dolasetron base and processes for preparation thereof
WO2007081835A2 (en) 2006-01-09 2007-07-19 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
EP1983823A1 (en) 2006-01-17 2008-10-29 VIB vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
US20070208072A1 (en) 2006-01-18 2007-09-06 Gustavo Frenkel Maleate salt of tegaserod and crystalline forms thereof
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
MX2007012605A (es) 2006-02-21 2008-01-11 Teva Pharma Formas cristalinas novedosas de armodafinil y preparacion de ellas.
TW200804279A (en) 2006-02-27 2008-01-16 Teva Pharma Fluvastatin sodium novel forms and preparation thereof
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
WO2007109799A2 (en) 2006-03-23 2007-09-27 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
PL3026044T3 (pl) 2006-06-26 2019-04-30 Akebia Therapeutics Inc Inhibitory prolilo-hydroksylazy i sposoby ich użycia
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
CA2683758A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
WO2008130508A1 (en) 2007-04-18 2008-10-30 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
US8309544B2 (en) 2007-05-16 2012-11-13 Merck Sharp & Dohme Corp. Spiroindalones
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CA2696725A1 (en) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
BRPI0820343A2 (pt) 2007-11-08 2017-08-22 Genentech Inc Anticorpos de antifator b e seus usos
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
NZ585701A (en) 2007-11-30 2012-09-28 Glaxosmithkline Llc Benzopyrazine derivatives as prolyl hydroxylase inhibitors
US20100305154A1 (en) 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
US20100298324A1 (en) 2007-12-19 2010-11-25 Smith Kline Beecham Corporation Prolyl Hydroxylase Inhibitors
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
NO2686520T3 (es) 2011-06-06 2018-03-17
JP2014522410A (ja) 2011-06-06 2014-09-04 アケビア セラピューティクス インコーポレイテッド がん治療のための方法として低酸素誘導因子−２αを安定化するための、化合物および組成物
JP6099644B2 (ja) 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
US8772895B2 (en) 2011-11-28 2014-07-08 Taiwan Semiconductor Manufacturing Company, Ltd. Dark current reduction for back side illuminated image sensor
EP2637274B1 (en) 2012-03-05 2022-05-04 Vetco Gray Scandinavia AS Power cable termination arrangement
DK3007695T3 (da) 2013-06-13 2024-03-18 Akebia Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af anæmi
JP2016537365A (ja) 2013-11-15 2016-12-01 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
US20160339005A1 (en) 2014-01-23 2016-11-24 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
EP3270922A4 (en) 2015-03-20 2018-08-01 Akebia Therapeutics Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
HRP20211862T1 (hr) 2015-04-01 2022-03-04 Akebia Therapeutics, Inc. Pripravci za i postupci liječenja anemije
EP3763703A3 (en) 2016-12-13 2021-03-03 Crystal Pharmaceutical (Suzhou) Co., Ltd. Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and processes for preparation thereof
AR114886A1 (es) 2018-05-09 2020-10-28 Akebia Therapeutics Inc Proceso para preparar ácido 2-[[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino]acético
MX2022005104A (es) 2019-10-31 2022-07-21 Akebia Therapeutics Inc Métodos terapéuticos mediante el uso de vadadustat.
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Also Published As

Publication number Publication date
TW202126300A (zh) 2021-07-16
WO2015073779A1 (en) 2015-05-21
DOP2016000109A (es) 2016-08-31
AU2020294308B2 (en) 2022-08-11
JP2019167353A (ja) 2019-10-03
KR102495018B1 (ko) 2023-02-06
CN114890943A (zh) 2022-08-12
US10596158B2 (en) 2020-03-24
US9701636B2 (en) 2017-07-11
TWI788702B (zh) 2023-01-01
CN105916502A (zh) 2016-08-31
IL281648A (en) 2021-05-31
BR112016011065B1 (pt) 2022-10-25
CR20160222U (es) 2016-08-26
RU2021125455A (ru) 2021-10-05
AU2019202144A1 (en) 2019-04-18
AU2019202144B2 (en) 2020-10-08
MX2021007268A (es) 2021-07-15
BR112016011065A8 (pt) 2020-04-22
KR20160083118A (ko) 2016-07-11
EP3068394A1 (en) 2016-09-21
US20200345711A1 (en) 2020-11-05
NZ759132A (en) 2022-03-25
AU2014348523B2 (en) 2019-01-03
ZA201905255B (en) 2020-11-25
TW201946625A (zh) 2019-12-16
JP2022176961A (ja) 2022-11-30
JP2016537365A (ja) 2016-12-01
JP2020183408A (ja) 2020-11-12
CA2930128A1 (en) 2015-05-21
SA516371129B1 (ar) 2019-07-28
PH12016500866A1 (en) 2016-06-20
TW202335670A (zh) 2023-09-16
US11065237B2 (en) 2021-07-20
AR099354A1 (es) 2016-07-20
US20150141467A1 (en) 2015-05-21
US20180280365A1 (en) 2018-10-04
US20170258773A1 (en) 2017-09-14
AU2014348523A1 (en) 2016-06-09
RU2016123382A (ru) 2017-12-20
KR102381295B1 (ko) 2022-03-31
NZ719970A (en) 2022-03-25
EP3578546A1 (en) 2019-12-11
CR20200220A (es) 2020-11-18
EP3068394A4 (en) 2017-04-26
US20190290624A1 (en) 2019-09-26
US11690836B2 (en) 2023-07-04
AU2020294308A1 (en) 2021-02-18
CL2016001150A1 (es) 2016-12-09
IL245634A0 (en) 2016-06-30
AU2022259767A1 (en) 2022-12-01
US9987262B2 (en) 2018-06-05
TW201605801A (zh) 2016-02-16
AR128483A2 (es) 2024-05-15
MA39033A1 (fr) 2017-11-30
US10149842B2 (en) 2018-12-11
KR20220042498A (ko) 2022-04-05
BR112016011065A2 (pt) 2017-08-08
SG10202012791TA (en) 2021-01-28
MY180626A (en) 2020-12-03
US20240122910A1 (en) 2024-04-18
ZA201603189B (en) 2019-11-27
MX2021001169A (es) 2023-02-10
TWI665190B (zh) 2019-07-11
SG10201803862UA (en) 2018-06-28
US20220040159A1 (en) 2022-02-10
PE20160945A1 (es) 2016-09-26

Similar Documents

Publication Publication Date Title
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
AU2018236800B2 (en) DNA-PK inhibitors
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
WO2015073587A3 (en) Synthetic membrane-receiver complexes
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
UA114476C2 (uk) Хіназолінові похідні для лікування вірусних інфекцій та подальших захворювань
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
JO3543B1 (ar) تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
WO2012123561A3 (de) Agens zur prophylaxe und behandlung altersassoziierter krankheiten und störungen sowie zur verlängerung der lebensdauer
PH12020500472A1 (en) Autotaxin inhibitor compounds
TWI846166B (zh) {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途